KR100404443B1 - Pharmaceutical composition for treating gastritis and peptic ulcer - Google Patents

Abstract

PURPOSE: A pharmaceutical composition including an Artemisia asiatica extract, H2 antagonists, proton pump inhibitors and colloidal bismuth compounds is provided. It exhibits better synergistic medicinal action than the effectiveness of each medicinal component and has excellent treatment effect on gastritis and peptic ulcer. CONSTITUTION: The pharmaceutical composition for the treatment of gastritis and peptic ulcer is characterized in that it contains an Artemisia asiatica extract together with an H2 antagonist, a proton pump inhibitor and a colloidal bismuth compound. For an example, 125.0mg Artemisia asiatica extract is mixed with 10.0mg famotidine, 182.0mg bean oil, 42.5mg bees wax, 127.5mg hardened palm oil, 21.0mg soybean phospholipid, 211.0mg gelatin, 65.0mg glycerin, 76.0mg di-sorbitol, 0.56mg methyl parahydroxybenzoate, 0.88mg propyl parahydroxybenzoate, 0.56mg methyl vanillin and a suitable amount of Yellow 203 to give a soft gelatin capsule.

Description

Pharmaceutical composition for treating gastritis and peptic ulcer

The present invention relates to a pharmaceutical composition for the treatment of peptic ulcer such as gastritis, gastric ulcer and duodenal ulcer, wherein the pharmaceutical composition of the present invention comprises extracts of Artemisia asiatica, A. mongolica, A. princeps, and A. argyi and gastric acid secretion inhibitory effect represents H ₂ inhibitors, proton pump inhibitors or attack factor despread prevention and H. pylori (Helicobacter pylori) colloidal showing the inhibitory functional bismuth compounds such as gastritis and peptic ulcer therapeutic agent composed of a drug constantly lesions irritation and pain caused by gastric acid for And gastrointestinal tract lesion healing by promoting mucin secretion and endogenous prostaglandin synthesis, and exhibits a synergistic effect in the treatment of gastritis and peptic ulcer.

The stomach is a long-term organ that stores the food from the esophagus, breaks it down easily, and controls the sending of food to the duodenum, thereby enabling efficient digestion and absorption by secretion and harmony of the pancreatic enzyme. The stomach secretes stomach acid, which is strong acid to digest when food comes in. At this time, the mucous membrane protects the gastric mucosa from being damaged by stomach acid. Inflammation occurs when the secretion of gastric acid is enhanced by various causes or when the gastric mucosal protective layer is damaged. When the inflammatory lesion is confined to the gastric mucosa, it is called gastric ulcer, when gastritis, ulcer formation through the gastric mucosa and submucosal tissue and muscle layer. Duodenal ulcers are called duodenal ulcers, and ulcers and duodenal ulcers are collectively called peptic ulcers.

This is called Balance Theory because peptic ulcers are caused by aggravation of attack factors or weakening of protective factors (Gastroenterology pp. 420, 1963). Among the attack factors, there are gastric acid, antiinflammatory agents, bacterial infection, and defense factors include mucus, cell regeneration, and alkaline secretion. Recently, Helicobacter pylori has been identified as an important cause of bacterial infection among the attack factors (Scan J. Gastroenterol 26 (suppl) 6, 1991).

Antacids, H ₂ inhibitors and proton pump inhibitors, or gastric mucosal protective agents, which are used for the inhibition of acid secretion, are mainly used as therapeutic agents for gastritis and peptic ulcer. Recently, for the purpose of removing Helicobacter pylori The use of antibiotics has been introduced. The antacid is characterized by its short duration (New Eng J Med 298: 1041, 1978) and its efficacy by lowering the pH of the stomach to lower the activity of pepsin (New Eng J Med 274: 921, 1966). However, administration of inorganic substances has been associated with constipation (J Int Med Res 6 (suppl) 11, 1978), diarrhea (Hepatogastroenterol 29: 135, 1982), metabolic alkalosis (Am J Dig Dis 11: 413, 1966) (J Clin Gastroenterol 15 (1): 37, 1992). Recently, there has been a problem of acid rebound due to antacids (Gastroenterologie 21 (suppl) 117, 1983).

In 1977, when cimetidine was first released, a full-fledged treatment for peptic ulcers began (J Int Med Res 17 (suppl 9A, 1989)). As the availability of the H ₂ inhibitor, cimetidine, has been known, a number of derivatives have been developed, including ranitidine, famotidine, roxatidine, nizatidine, (Meth Find Exp Exp Clin Pharmacol 11 (suppl 1) 87, 1989, N Eng J Med 323: 1672, 1990). However, a high recurrence rate has been a problem after administration Drug Intell Clin Pharm 21: 493, 1987, Gut 30: 449, 1989). This is because the mucous membrane and submucosal tissues healed by these attack factor inhibitors are weaker than normal tissues, and they are easily damaged by attack factors such as acidosis after drug administration (J Clin Gastroenterol 11 suppl 1) S34, 1989).

A relatively recently developed proton pump inhibitor, omeprazole and lansoprazol, are known to inhibit acid secretion in the gastric wall cells at the final stage (Yale J Biol Med 65 : 649, 1992). The recurrence rate has not been reduced in patients with ulcer healing due to these agents, and side effects such as Yanbyeon, diarrhea, fever, headache and fatigue have been reported.

Therefore, when H ₂ inhibitor and proton pump inhibitor alone are used for the inhibition of gastric acid secretion, the most important inhibitory effect on recurrence of peptic ulcer is not expected.

In the case of the gastric mucosal protective agent, it is known that the mucosal protective agent generally has a low short-acting effect, has a high dosage, and should be taken for a relatively long period of time. However, . Helicobacter pylori and non-steroidal anti-inflammatory drugs are known to play an important role in the recurrence of peptic ulcer (Scan J Gastroenterol 26 (suppl): 6, 1991) The recovery of the host factor, such as structural normalization, is very important for lowering the recurrence rate. Therefore, it is urgent to introduce treatment that can reduce the recurrence rate as well as shortening the duration of peptic ulcer healing, that is, improving the quality of ulcer healing.

The present inventors have been studying for the development of a therapeutic agent for gastritis and peptic ulcer, and found that the mugwort extract has an effect of treating gastritis and peptic ulcer, and has filed a patent application.

Mugwort is a perennial herbaceous plant belonging to Compositae and has a unique aroma and taste. Young leaves have been used for food such as mugwort cake and have been known to be effective for bleeding of uterus and bleeding during pregnancy by warming the uterus in one room, and it has been used as a treatment for hypertension, gynecological diseases and diarrhea (东 醫 寶 鑑). As the pharmacological action of mugwort, the water extract of mugwort prolongs blood coagulation time (Pharmacology Journal 28 (2): 69-77, 1984). Flavone extracted from mugwort has been reported to have anticancer activity (Chem. Pharm. Bull. 39 (8): 2077-7, 1992), platelet aggregation inhibitory action (Zhongguo Zhongyao Zazhi, 17 (6) 2081, 1991).

The inventors of the present invention have continued intensive research on mugwort. Especially, while trying to clarify the medicinal properties of native mugwort, the inventors found that mugwort has a gastric mucosal protective effect other than the above-mentioned pharmacological action, (Patent Application No. 95-21957), and the use of the extract as a therapeutic agent for gastrointestinal diseases (Patent Application No. 95-21957). In addition, jaceosidin and eupatilin were separated from mugwort, and it was found that this oil tiline and posture oocidine were effective as therapeutic agents for gastrointestinal diseases (Patent Application No. 94-147, 94-39337 (Patent Application No. 96-28230), which has been known to be effective against inflammatory bowel disease, which is known to have no specific drug.

The inventors of the present invention found through continuous research that mugwort extract does not affect gastric acid secretion and exhibits a mucosal protective effect such as promoting mucus secretion. As described in the patent application already filed by the present applicant, 95-21957) itself not only shows therapeutic effects on gastritis and peptic ulcer, but also can be used in combination with H ₂ blocker and proton pump inhibitor, which are gastric acid secretion inhibitors, which are drugs for gastritis and peptic ulcer treatment, and colloidal bismuth compound The present invention provides a synergistic synergistic effect.

The present invention relates to a pharmaceutical composition comprising mugwort extract, a drug for treating gastritis and peptic ulcer, and the like.

The drug for treating gastritis and peptic ulcer of the present invention may include an H ₂ blocker, a proton pump inhibitor and a colloidal bismuth compound.

The pharmaceutical composition of the present invention may be composed of mugwort extract and H ₂ blocker.

The pharmaceutical composition of the present invention may be composed of mugwort extract and proton pump inhibitor.

The pharmaceutical composition of the present invention may be composed of mugwort extract and colloidal bismuth compound.

The H ₂ blocking agent used in the present invention may include famotidine, ranitidine, cimetidine, etc. The proton pump inhibitor may include omeprazole, and the colloidal bismuth compound may include a bismuth supercritical rate.

The method for producing the mugwort extract used in the present invention is described in detail in a patent application (Patent Application No. 95-22957) filed by the applicant of the present invention, the contents of which can be summarized as follows.

≪ Reference Example 1 &

100 g of dried wormwood leaves are frozen twice with 1 l of 70% ethanol for 24 hours at room temperature, and the extracted filtrate is concentrated under reduced pressure and lyophilized to obtain a solid content of 10.8 g. The content of milk tilline was 0.449% and the content of postural osteine was 0.277%.

<Reference Example 2>

100 g of the fine wormwood leaves are refluxed twice with 4 liters of 70% ethanol for 4 hours. The extract is concentrated under reduced pressure and lyophilized to obtain a solid content of 16.2 g. The content of milk tilline was 0.412% and the content of postural osteine was 0.225%.

<Reference Example 3>

100 g of dried wormwood is ultrasonically extracted with 1 l of 70% ethanol for 4 hours at room temperature for 2 hours, and the extracted filtrate is concentrated under reduced pressure and lyophilized to obtain a solid content of 12.8 g. The content of milk tiline was 0.443% and the content of postural osteine was 0.252%.

<Reference Example 4>

100 g of the fine wormwood leaves are frozen twice with 1 liter of 90% ethanol for 24 hours at room temperature, and the extracted filtrate is concentrated under reduced pressure and lyophilized to obtain 7.2 g of a solid. The content of milk tilline was 0.734% and the content of posture osteine was 0.513%.

<Reference Example 5>

100 g of the fine wormwood leaves are refluxed for 2 hours with 1 l of 90% ethanol for 4 hours. The extract is concentrated under reduced pressure and lyophilized to obtain a solid content of 13.4 g. The content of milk tiline was 0.823% and the content of posture osteine was 0.493% in the solid contents.

<Reference Example 6>

100 g of the wormwood leaves are ultrasonically extracted twice with 1 l of 90% ethanol for 4 hours at room temperature. The extract is concentrated under reduced pressure and lyophilized to obtain 9.7 g of a solid. The content of milk tiline and porcine osteidine in solid contents were 0.896% and 0.487%, respectively.

<Reference Example 7>

100 g of dried wormwood leaves are cooled with 1 l of 95% ethanol at room temperature for 24 hours twice, and the extracted filtrate is concentrated under reduced pressure and lyophilized to obtain 5.0 g of a solid. The content of milk tilline was 1.010% and the content of posture osteine was 0.640%.

<Reference Example 8>

100 g of the fine wormwood leaves are refluxed for 2 hours with 1 l of 95% ethanol for 4 hours. The extracted filtrate is concentrated under reduced pressure and lyophilized to obtain a solid content of 10.3 g. Among the solids, the content of milk tilline was 0.994% and the content of postural osteine was 0.565%.

<Reference Example 9>

100 g of the fine wormwood leaves are ultrasonically extracted with 1 l of 95% ethanol for 4 hours at room temperature for 2 hours, and the extracted filtrate is concentrated under reduced pressure and lyophilized to obtain a solid content of 9.7 g. The content of milk tiline was 0.987% and the content of posture oystin was 0.534%.

<Reference Example 10>

100 g of the fine wormwood leaves are cooled with 1 l of 100% ethanol for 24 hours at room temperature for 2 hours, and the extracted filtrate is concentrated under reduced pressure and freeze-dried to obtain 5.2 g of a solid. The content of milk tiline was 1.284% and the content of posture osteine was 0.649%.

<Reference Example 11>

100 g of the fine wormwood leaves are refluxed with 1 l of 100% ethanol for 4 hours twice, and the extracted filtrate is concentrated under reduced pressure and lyophilized to obtain a solid content of 8.9 g. In the solids, the content of milk tiline was 1.129% and the content of porcine oystine was 0.638%.

<Reference Example 12>

100 g of dried wormwood leaves are ultrasonically extracted with 1 l of 100% ethanol for 4 hours at room temperature. The extract is concentrated under reduced pressure and lyophilized to obtain 7.1 g of a solid. The content of milk tilline was 0.978% and the content of posture osteine was 0.541% in the solid contents.

<Reference Example 13>

100 g of dried wormwood leaves were cooled with 800 ml of 95% ethanol for 24 hours at room temperature, and the extracted filtrate was concentrated under reduced pressure to 1/150, and then 7.0 g of lactose and 3.0 g of corn starch were added thereto and passed through a 20- Followed by hot air drying at 80 DEG C to obtain a solid content of 14.8 g. The content of milk tilline was 0.429% and the content of posture osteine was 0.231%.

<Reference Example 14>

100 g of dried wormwood leaves are cooled with 800 ml of 95% ethanol for 24 hours at room temperature twice, and the extracted filtrate is concentrated under reduced pressure to 1/100, then 0.5 g of texturin is evenly dispersed and then spray dried to obtain 13.9 g of solid content. The content of milk tilline was 0.417% and the content of postural osteine was 0.277% in the solid contents.

&Lt; Referential Example 15 >

100 g of dried wormwood leaves are cooled with 800 ml of 95% ethanol at room temperature for 24 hours twice, and the extracted filtrate is concentrated under reduced pressure and lyophilized to obtain 5.0 g of a solid. Among the solids, the content of milk tiline was 1.312% and the content of porcine oysteine was 0.667%.

<Reference Example 16>

100 g of the fine wormwood leaves are cooled with 1,000 ml of water twice at room temperature for 24 hours, and the filtrate is discarded. 700 ml of 100% ethanol is added to the extracted residue, the mixture is cooled for 24 hours, filtered, and 700 ml of 70% ethanol is added. The extracted filtrate was combined, concentrated under reduced pressure, and then lyophilized to obtain a solid content of 4.7 g. The content of milk tiline was 1.274% and the content of posture osteine was 0.673%.

The effect of the pharmaceutical composition comprising the mugwort extract, the H ₂ inhibitor, the proton pump inhibitor or the colloidal bismuth compound on the quality of gastric and peptic ulcer treatment in an artificially induced gastritis and peptic ulcer animal model is shown in the examples I will explain in detail. The embodiments of the present invention are illustrative of the contents of the present invention, and the contents of the present invention are not limited thereto.

I. Drug test

The ascertaining effect of the pharmaceutical composition comprising the mugwort extract, the H ₂ inhibitor, the proton pump inhibitor or the cystic bismuth compound on the quality of treatment of gastritis and peptic ulcer obtained in the above Referential Example can be confirmed by the statistical method of Okabe The Okabe method (Pharmacometrics 12: 759, 1976) and the recently introduced statistical test method Laska method (Biometrics 50: 834, 1994) were used.

The synergy test in the Okabe method is judged to be a synergistic effect when the value obtained by multiplying the incidence of ulcers occurring when each drug is administered alone is greater than the incidence rate obtained when the drug is used in combination. An ED ₅₀ value indicating a 50% effective dose was used. The synergistic assays in the Laskar method were significantly higher than those of the second and third groups in the one-side Student t-test for each drug group in the first group after obtaining the ED ₅₀ of each drug It is recognized as a synergistic effect.

Group 1: Drug A, B combined use group (ED ₅₀ of the drug A 1/2 + 1/2 Drug ED ₅₀ of B)

Group 2: Drug A administered group (1/2 ED ₅₀ of drug A + 1/2 ED ₅₀ x 1 / r of drug B), r = 0.25 (expected value)

Group 3: Drug B treated group (1/2 ED ₅₀ x r of drug A + 1/2 ED ₅₀ of drug B), r = 0.25 (expected value)

Example 1: Mugwort extract and H ₂ Synergism with inhibitors

The synergistic action of the H ₂ inhibitor with the mugwort extract was examined using the Laskar method (Biometrics 50: 834, 1994) for indomethacin-induced gastric lesions. Famotidine, ranitidine and cimetidine were used as H ₂ inhibitors. Seven weeks old male rats were fasted for 24 hours, and oral administration of each drug was followed by oral administration of indomethacin 40 mg / kg 1 hour later. All animals were slaughtered 6 hours after the administration of indomethacin, the stomach was excised and the ulcer area was measured and ascertained. The test results are shown in Tables 1 to 3.

The synergistic action of the medicinal composition comprising mugwort extract and famotidine on the indomethacin-induced gastric ulcer is shown in Table 1, and the synergistic action of the medicinal composition comprising mugwort extract and ranitidine is shown in Table 2. The synergistic action of the mugwort extract and cimetidine The synergistic action of the pharmaceutical composition is shown in Table 3.

[Table 1]

Synergism between Mugwort extract and famotidine on indomethacin-induced gastric ulcer

[Table 2]

Synergistic Action of Mugwort Extract and Ranitidine on Indomethacin-Induced Gastric Ulcer

[Table 3]

Synergistic Effect of Mugwort Extract and Cimetidine on Indomethacin-Induced Gastric Ulcer

As can be seen from Tables 1, 2 and 3, the pharmaceutical composition comprising mugwort extract, famotidine, mugwort extract, lanitidine, mugwort extract and cimetidine showed excellent synergistic effect in the indomethacin- . &Lt; / RTI &gt;

The synergistic action of mugwort extract and famotidine by the above-mentioned Okabe method (Pharmacometrics 12: 759, 1976) in the same indomethacin gastric ulcer model is shown in Table 4.

[Table 4]

Synergistic action of mothi extract and famotidine on indomethacin-induced gastric ulcer - Okabe method

As can be seen from the above Table 4, the pharmaceutical composition comprising mugwort extract and famotidine shows excellent effects in the indomethacin-induced gastric ulcer model in all dose groups.

Example 2 Synergistic Effect of Mugwort Extract and Proton Pump Inhibitor

The uptake of omeprazole and mugwort extract, which are representative proton pump inhibitors, was investigated using the above-mentioned Okabe method (Pharmacometrics 12: 759, 1976) for absolute ethanol-induced gastric lesions. Seven-week-old male rats were fasted for 24 hours and each drug was orally administered. After 1 hour, anhydrous ethanol was orally administered at 1.5 ml per mouse. After 1 hour of ethanol administration, all animals were slaughtered and the stomach was excised and the lesion area was measured and ascertained synergy. The test results are shown in Table 5.

[Table 5]

Synergistic Action of Mugwort Extract and Omeprazole on Anhydrous Ethanol-Induced Gastric Lesions - Okabe Method

As can be seen from Table 5, it can be seen that the pharmaceutical compositions comprising mugwort extract and Oprameseol synergistically reduce gastric lesion sites induced by anhydrous ethanol in all the dose groups and synergistically decrease lesion expression rates.

Example 3 Synergism between Mugwort Extract and Colloidal Bismuth Compound

The colloidal bismuth bismuth subcitrate and the mugwort extract were prepared by using the above-mentioned Okabe method (Pharmacometrics 12: 759, 1976) for stomach lesions by ethanol-HCl. . Seven weeks old male rats were fasted for 24 hours and each drug was orally administered. After 1 hour, the ethanol / hydrochloric acid mixture was orally administered at 1.0 ml per mouse. One hour after the administration of ethanol-hydrochloric acid, all animals were slaughtered and the stomach was excised and the area of the lesion was measured to confirm the synergy. The test results are shown in Table 6.

[Table 6]

Synergistic Effect of Mugwort Extract and Bismuth Supercritice on Ethanol-Hydrochloric Acid-Induced Gastric Lesions-Okabe Method

As can be seen from Table 6, it can be seen that the pharmaceutical compositions comprising mugwort extract and bismuth suppository rate synergistically reduce the area of gastric ulcer caused by ethanol-hydrochloric acid in all dose groups and synergistically decrease the lesion expression rate .

Ⅱ. Effect of Mugwort Extract on the Quality of Ulcer Healing

&Lt; Example 4 > ₂ Synergism with inhibitors

The effects of mugwort extract on the quality of ulcer healing of acetic acid - induced gastric ulcer, the most widely used experimental subchronic ulcer model, were investigated. The gastric ulcer model by acetic acid was prepared by anesthetizing 6-week-old rats according to the standard method (Gastroenterology 95: 636, 1988), contacting acetic acid to the gastrointestinal membranes and then suturing again. After the first day of ulcer induction, the drug was orally administered once a day for 4 weeks. At 2 and 4 weeks after the drug administration, a portion of each group was autopsied to excise the stomach and evaluate the ulcer healing level (Gastroenterologica japonica 17 (6) 530, 1982, J Clin Gastroenterol 13 (suppl 1): S42, 1991) and Dunn test after Cruskal-Wallis ANOVA. The test results are shown in Table 7 and Table 8.

[Table 7]

Drug administration 2 weeks Severity of ulcer healing

[Table 8]

Drug administration 4 weeks Severity of ulcer healing

As can be seen in Tables 7 and 8, the PAS-AB staining of the regenerated mucosa at 2 weeks after administration of the drug and the degree of fibrosis at the bottom of the ulcer were significantly improved in ranitidine alone group But the mugwort extract-treated group and the mugwort extract-treated ranitidine group of Reference Example 15 showed significant mucosal fidelity and fibrosis recovery. In addition, there was no significant difference in PAS-Alcian blue staining, indicating maturity of regenerated mucosa, but maturity was high due to strong PAS staining compared with control. The degree of fibrosis (cell density) of the healed ulcer bottom at 4 weeks after administration was not different between the groups, but the degree of vasculization and normalization of regenerated mucosa at the bottom of ulcer And mugwort extract and ranitidine showed a significant recovery in comparison with the control group.

These results indicate that the mugwort extract exhibits a synergistic effect when used in combination with an H ₂ inhibitor, a proton pump inhibitor or a colloidal bismuth compound in comparison with an animal model of gastritis and peptic ulcer. By combining these drugs with mugwort extract It is possible to introduce safe and useful peptic ulcer treatment such as reduction of recurrence rate due to excellent therapeutic effect and recovery of host factors as well as reduction of side effects of these drugs by decreasing dose.

Hereinafter, the present invention will be described as an example of the formulation according to the present invention. The contents of the present invention are not limited to these formulation examples, and the formulation examples can be modified in various ways.

&Lt; Formulation Example 1 > Preparation of soft capsule

In accordance with the general procedure for the preparation of soft capsules, one capsule contains the following ingredients.

95% Ethanol wormwood extract 125.0 mg

Famotidine 10.0 mg

Soybean oil 182.0 mg

Yellow phosphorus 42.5 mg

Palm kernel oil 127.5 mg

Soybean phospholipids 21.0 mg

Gelatin 211.0 mg

Glycerin 65.0 mg

Di-sorbitol 76.0 mg

P-hydroxybenzoate 0.56 mg

P-hydroxybenzoic acid propyl ester 0.88 mg

0.56 mg of methyl vanillin

Yellow color 203

&Lt; Formulation Example 2 > Preparation of capsule

The following ingredients are mixed homogeneously and filled in one capsule containing 550 mg.

95% ethanol cold extract Extract 125.0 mg

Omeprazole enteric granules 170.0 mg (15mg as omeprazole)

Corn starch 170.0 mg

Magnesium stearate 2.0 mg

&Lt; Formulation Example 3 > Preparation of capsule

The following ingredients are mixed homogeneously and filled in one capsule to contain 550 mg.

100% Ethanol wormwood extract 125.0 mg

Bismuth subsidence rate 170.0 mg

Corn starch 83.0 mg

Lactose 170.0 mg

Magnesium stearate 2.0 mg

&Lt; Formulation Example 4 > Preparation of tablets

The following ingredients are mixed homogeneously and granulated by a wet granulation method. Magnesium stearate is added to the mixture, which is then mixed to be tableted so that one tablet is 450 mg.

95% Ethanol wormwood extract 125.0 mg

Ranitidine 50.0 mg

Corn starch 85.0 mg

Lactose 170.0 mg

El-hydroxypropylcellulose 12.0 mg

Polyvinylpyrrolidone 90 6.0 mg

Ethanol quantity

-------------------------------------------

Magnesium stearate 2.0 mg

The pharmaceutical composition of the present invention is composed of mugwort extract, a drug for treating gastritis and peptic ulcer, and has excellent therapeutic effect on gastritis and peptic ulcer, and exhibits synergistic effect far superior to that of each drug.

In addition, the mugwort extract promotes the maturation and normalization of the regenerated mucosa in the ulcer healing process and increases mucosal protection such as increasing the angiogenesis in the lesion area, thereby helping the lesion to recover. Thus, the pharmaceutical composition of the present invention can be used as an H ₂ inhibitor, It inhibits the recurrence rate, which is a problem in peptic ulcer treatment by proton pump inhibitors, and shortens the treatment period. In addition, the mugwort extract has little side effects such as being used for edible purposes, and by reducing the dose of these drugs when used in combination with an H ₂ inhibitor, a proton pump inhibitor, or a colloidal bismuth compound, the pharmaceutical composition of the present invention is more safe Lt; / RTI &gt;

Claims (5)

Mugwort extract, and a drug for treating gastritis and peptic ulcer. The pharmaceutical composition according to claim 1, wherein the drug for treating gastritis and peptic ulcer comprises an H ₂ inhibitor The pharmaceutical composition according to claim 1, wherein the drug for treating gastritis and peptic ulcer comprises a proton pump inhibitor The pharmaceutical composition according to claim 1, wherein the drug for treating gastritis and peptic ulcer comprises a colloidal bismuth compound The pharmaceutical composition according to claim 1, wherein the drug for treating gastritis and peptic ulcer comprises at least one drug selected from an H ₂ inhibitor, a proton pump inhibitor and a colloidal bismuth compound